Takeda’s TAK-442 Enters Phase II Development
Japan drugmaker Takeda Pharmaceutical’s investigational compound TAK-442 has entered Phase II studies in the U.S. and Europe.
TAK-442 is a novel Factor Xa inhibitor developed by Takeda.
Factor Xa (FXa) plays a role in the blood coagulation cascade. Inhibition of FXa is expected to result in interruption of either venous or arterial thromboembolism, Takeda said.